Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
Healius Shares Rise 3.61% as AGM Highlights Strategic Progress and FY27 Outlook
Highlights:
Healius Limited (ASX: HLS), an Australian healthcare company specialising in pathology and diagnostic services, attracted investor attention on 23 October 2026 after outlining its operational progress and strategic priorities at its Annual General Meeting (AGM). The company’s AGM-related announcements covered shareholder voting results, financial performance and its outlook for FY27. According to the supplied market data, Healius shares were last quoted at AU$0.430, up AU$0.015 or 3.614% on the day.
Shareholders Reject Remuneration Report
In its announcement dated 22 October 2026, Healius confirmed that shareholders voted against adopting the FY26 Remuneration Report. The resolution received 349.8 million votes against, representing 76.29% of votes cast, compared with 108.7 million votes in favour.
With opposition exceeding 25% of the votes cast, Healius recorded its first remuneration strike under the Corporations Act. Other resolutions passed at the meeting included the re-election of Charlie Taylor as a director, the election of Bruce Robinson and Steven Rubic, and approvals relating to the Non-Executive Director Share Plan and remuneration arrangements for the chief executive officer.
FY26 Financial Performance and Operational Improvements
Healius reported a 2.1% increase in group revenue to AU$1.37 billion for FY26. Underlying EBITDA rose 8.1% to AU$258.6 million, while underlying EBIT increased 76.6% to AU$30.2 million. The company attributed its progress to improved operational performance, disciplined cost management and a stronger revenue mix. Its T27 strategy continues to focus on simplifying operations, modernising laboratories, improving customer service and expanding digital capabilities. During FY26, the company delivered annualised corporate cost savings of AU$24.4 million. It also reported progress in laboratory automation, digital referrals and AI-assisted operational processes.
FY27 Outlook and Strategic Developments
Managing Director and CEO Paul Anderson reaffirmed the FY27 EBIT guidance previously provided with the full-year results. Pathology revenue increased 1.6% in the first quarter of FY27 despite a 4.9% decline in episode volumes. Excluding the impact of two lost major hospital contracts and a reduced ACC footprint, like-for-like episode volumes grew 1.1%. The average fee increased 6.0%, supported by stronger revenue from hospitals, genomics, veterinary diagnostics and commercial contracts.
Healius has agreed to divest Agilex Biolabs to Novotech in a transaction valued at AU$160 million. The deal remains subject to regulatory clearance and customary closing requirements, with completion anticipated in the second half of FY27. Once finalised, the sale is expected to improve Healius’ financial flexibility and allow management to concentrate more closely on expanding its core pathology operations.
Conclusion
Healius’ latest AGM updates highlight improved underlying earnings, continued operational transformation and a reaffirmed FY27 outlook. However, the remuneration strike and ongoing healthcare-sector cost pressures remain important considerations for investors.
Note: All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au